Kolon TissueGene, Inc.

Languages

  • English
  • Korean
  • Korean
  • About
    • Overview
    • History
    • Management Team
    • Board of Directors
    • Advisory Boards
  • Technology
    • Overview
    • TG-C
    • Publications
  • Product Pipeline
    • Overview
    • 적응증 확장
  • Clinical Trials
  • IR
    • 주가정보
    • PR
    • IR Material
    • 공시
    • Analyst Report
  • Partnering/Alliances
  • Contact

PR

IR

IR

  • 주가정보
  • PR
  • IR Material
  • 공시
  • Analyst Report

Kolon TissueGene To Expand Indications For TG-C

Dec 3, 2021

Kolon Tissuegene Announces Plans To Resume US Phase III Clinical Trial For TG-C

Apr 13, 2020

Kolon TissueGene Doses First Patient in US Phase III Clinical Trial

Nov 21, 2018

Kolon TissueGene to Expand License Agreement for INVOSSA™ with Kolon Life Science

Jun 26, 2018

TissueGene Announces Company Name Change To Kolon TissueGene, Inc.

Mar 16, 2018

TissueGene To Present Clinical Trial Data For Its Cell And Gene Therapy For Osteoarthritis At Cell Therapy World Asia 2017

Sep 15, 2017

TissueGene Recognized During Maryland Commerce, State Departments' Week-Long Trade Mission To South Korea

Sep 11, 2017

TissueGene Awarded $750,000 Maryland Stem Cell Grant for Invossa™ Clinical Study

Jun 30, 2017

TissueGene to Highlight Invossa™, the World's First Cell-Mediated Gene Therapy for Degenerative Osteoarthritis, at JP Morgan Healthcare Conference

Jan 9, 2017

TissueGene Licensee, Kolon Life Science, Partners with Mitsubishi Tanabe Pharma to Develop and Commercialize Invossa™, the World's First Cell-Mediated Gene Therapy for Degenerative Osteoarthritis

Nov 1, 2016
  • 1
  • 2
© 2023 Kolon TissueGene, Inc. All Rights Reserved.

This information—including product information—is intended only for residents of the United States. The products discussed on this site may have different labeling in different countries.

Privacy Policy Disclaimer Sitemap Ethical Management